Recent Comments

Comment RSS

Adcirca News and Research RSS Feed - Adcirca News and Research

Adcirca is a once-daily phosophodiesterase-5 (PDE-5) inhibitor for Pulmonary Arterial Hypertension (PAH) (WHO Group I) that improves your ability to exercise.

Third quarter 2009 financial results announced by United Therapeutics

29. October 2009 07:37
United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , ,

Permalink | Comments (0)

FDA approves Adcirca (tadalafil) tablets for pulmonary arterial hypertension

26. May 2009 05:40
United Therapeutics Corporation announced today that the United States Food and Drug Administration (FDA) has approved Adcirca (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). [More]

Posted in: Pharmaceutical News

Tags: , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.